"上次车祸后，我再也不敢坐副驾了，一上车就心慌手抖" "被欺负后，我总在梦里回到那天，惊醒时浑身是汗" "亲眼看到意外发生，现在听到巨响就忍不住发抖"…… 生活中，总有人在经历某件事后"像变了个人"——从前爱笑的人变得沉默，曾经勇敢的人变得怯懦，甚 至会回避所有与创伤相关的人和事。 很多人会随口说"这就是PTSD吧"，甚至把它当成一句玩笑或调侃。但当这种状态持续不退，影响到睡 眠、工作和正常生活时，它可能已不再是简单的"心理阴影"。 今天，北京安定医院副主任医师孟繁强将从精神心理专业角度，带您读懂创伤后应激障碍（PTSD）的 真相，教您识别危险信号，学会科学应对与支持。 一、医学上的PTSD，和你听说的不一样 1.PTSD是什么？ 在精神医学诊断标准中，创伤后应激障碍有严谨且明确定义：个体经历或目睹异乎寻常的威胁性或灾难 性事件后，产生的长期、持续的精神障碍。 这与网络用语有本质区别。日常玩笑说的"我PTSD了"，多是对短暂负面情绪的调侃，程度轻、时间 短，不影响社会功能，一般不构成病理状态；而医学上的PTSD症状往往持续一个月以上，并导致工 作、社交等基本社会功能受到实质性损害。 简单来说，网络用语中的"P ...

Core Insights - The Israeli military is experiencing a significant increase in PTSD cases and suicide incidents among soldiers due to ongoing conflicts in Gaza, Lebanon, and Syria, raising concerns about the mental health of its troops [2] Group 1: PTSD and Mental Health Statistics - Since September 2023, PTSD cases among soldiers have increased by nearly 40%, with projections indicating a rise of 180% by 2028 [2] - Currently, 60% of the 22,300 soldiers receiving treatment for war-related injuries are suffering from PTSD [2] - A report from Maccabi Healthcare Services indicates that 39% of treated soldiers seek mental health support, and 26% express concerns about depression [2] Group 2: Suicide Attempts and Military Response - From January 2024 to July 2025, 279 soldiers are expected to attempt suicide, a significant increase compared to previous years, with frontline soldiers accounting for 78% of these cases [2] - The Israeli Defense Ministry has expanded mental health services and increased its budget in response to the rising mental health issues among soldiers [2] Group 3: Barriers to Accessing Mental Health Support - Soldiers must attend a Defense Ministry assessment committee to receive national mental health support, a process that can take months and may deter them from seeking help [3] - Experts indicate that Israel's mental health institutions are overwhelmed, leading to many individuals being unable to access treatment or even recognize the connection between their suffering and their experiences [3]

Financial Data and Key Metrics Changes - The company has accelerated its timeline for commercialization by nine to twelve months due to successful enrollment in clinical trials and positive dialogue with the FDA [59][63] - The 26-week data from the O6 trial is now expected to be available in early Q3, which is earlier than previously guided [59] Business Line Data and Key Metrics Changes - The company is preparing for the launch of COMM-360, which is expected to be administered at sites currently delivering SPRAVATO, indicating a smooth transition for existing treatment centers [9][10] - The company has made significant progress in strategic collaborations and market access work to ensure a solid understanding of the marketplace landscape [40][41] Market Data and Key Metrics Changes - The company anticipates that a significant number of the approximately 6,000 interventional psychiatry centers capable of administering multi-hour treatments will be certified to deliver COMM-360 at launch [50][55] Company Strategy and Development Direction - The company is focused on building a strong commercial strategy, including marketing, messaging, and payer discussions, to ensure successful market entry [41][42] - The company is also exploring broader access to treatment beyond interventional psychiatry sites, reflecting a commitment to equitable access [55] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential for accelerated timelines and the positive relationship with the FDA, which is crucial for the development of psychedelic treatments [48][63] - The company is preparing for an advisory committee meeting with the FDA and is confident in its data collection and risk-benefit characterization for COMM-360 [52][51] Other Important Information - The company has finalized the protocol for PTSD studies and is looking forward to initiating the first patient in Q1 of the following year [64] - The company is actively engaging with the VA to ensure access to treatments upon approval [26] Q&A Session Summary Question: Selection of specialty pharma partner for patient access - The company has not yet selected a partner but is working on understanding distribution pathways and will narrow down options in the coming months [6][7] Question: Administration of COMM-360 at SPRAVATO sites - Any site delivering SPRAVATO today is expected to be capable of delivering COMM-360 if approved, although some incremental changes may be needed [9][10] Question: FDA engagement and data expectations - The company expects to have another meeting with the FDA after releasing significant data in Q1, which will help align on the plan going forward [15][61] Question: Commercialization preparation for March - The company has pulled forward traditional commercial activities and is ready to engage in payer discussions based on upcoming data [41][42] Question: Change in FDA's tone regarding COMM-360 - The company noted a positive change in tone from the FDA, indicating a supportive relationship while maintaining high standards [48][49] Question: Readiness of SPRAVATO infrastructure for COMM-360 - The company is leveraging existing collaborations to ensure that interventional psychiatry sites are prepared to deliver COMM-360 at launch [55]

Core Points - A tragic plane crash involving a Boeing 787 occurred shortly after takeoff from Ahmedabad Airport, resulting in the deaths of 265 individuals, including 241 passengers and at least 24 ground staff [2] - This incident marks the first fatal accident for the Boeing 787 in its 14 years of service and is one of the deadliest aviation disasters since the 2014 Malaysia Airlines incident [2] Group 1: Survivor Stories - Bomi Choksi, a passenger who missed the flight due to a traffic jam, reflects on her narrow escape from the disaster, realizing that her delay saved her life [4] - Vishwashkumar Ramesh, the only surviving passenger, describes the chaotic moments during the crash and his miraculous escape through an unexpectedly opened emergency exit [8] - Both survivors face significant psychological burdens, with Ramesh grappling with survivor's guilt after losing his brother in the crash, while Choksi experiences feelings of "survivor's guilt" for outliving others [11] Group 2: Reflections on Fate and Life - The ongoing investigation into the crash will determine the cause, whether mechanical failure, bird strike, or human error, highlighting the unpredictability of fate [14] - The experiences of the survivors underscore the fragility of life and the importance of cherishing every moment, as their survival was influenced by a series of random events [14]

Financial Data and Key Metrics Changes - As of March, the company had cash and cash equivalents of $260 million, an increase from $165 million at the end of 2024, indicating a strong financial position following recent financing [12] - Cash used in operations for the first quarter was $45.7 million, with an expected net cash usage for the full year 2025 projected to be between $120 million to $145 million [13] Business Line Data and Key Metrics Changes - The company announced the completion of dosing for all participants in Part A of its pivotal Phase III trial for treatment-resistant depression (TRD), with top-line results expected in late June [5] - The Phase III program aims to confirm the durability and safety profile of COMM360, which could provide a groundbreaking treatment option for TRD patients if successful [9] Market Data and Key Metrics Changes - The company is focusing on the commercialization of COMM360 by developing relationships with various provider types through strategic collaborations, including a new partnership with HealthPort to enhance access to innovative mental health treatments [10] Company Strategy and Development Direction - The company is preparing for the commercialization of COMM360 by understanding the commercial opportunity and ensuring broad delivery across various care settings [9] - The strategic collaboration with HealthPort aims to address the needs of underserved populations, reflecting the company's commitment to equitable access to mental health treatments [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming Phase III data readout, emphasizing the potential of COMM360 to be a clinically differentiated treatment option for TRD [13] - The company is also working on the final design for a late-stage clinical program in PTSD, indicating a significant commercial opportunity in this area due to high unmet needs [13] Other Important Information - The independent Data Safety Monitoring Board (DSMB) is regularly reviewing unblinded safety data, with a focus on suicidality, which remains a critical concern in the context of TRD [6][39] Q&A Session Summary Question: Key takeaways from the long-term follow-up data on durability and appropriate dosing - Management noted that while the data is not definitive, it suggests that patients receiving 25 mg can experience effects lasting up to six months, indicating this dose may be preferred moving forward [21] Question: Efficacy delta on MADRS and placebo effect considerations - Management acknowledged the variability in placebo effects in psychedelic trials and estimated a clinically significant effect size of over three on the MADRS scale [29] Question: Concerns regarding suicidality signals - Management clarified that suicidality is a core feature of depression and must be included in study designs, with ongoing monitoring to ensure safety [36] Question: Current delivery of esketamine by HealthPort - HealthPort has experience delivering SPRAVATO and is motivated to ensure access to new treatment options for underserved populations [42] Question: Manufacturing supply chain and FDA inspections - The company is currently manufacturing in the UK and plans to add US manufacturing capabilities, with multiple inspections conducted over the years [49] Question: Patient enrollment in COMM-five and comparison to Phase 2b - Management confirmed that recruitment criteria remain consistent, suggesting similar patient profiles across studies [55] Question: Interest in large pharma partnerships - The company is committed to commercializing COMM360 independently in the US, with no current plans for large pharma partnerships [58] Question: Optimal time frame for assessing suicidality risk post-treatment - Management indicated that predictions are difficult, and they will rely on data to inform their understanding of suicidality risk [61] Question: Changes in FDA interactions regarding psychedelic therapies - Management reported no significant changes in FDA interactions, maintaining routine discussions around event reporting [63]

Group 1 - The article discusses the concept of prolonged grief disorder, which refers to a persistent grief response triggered by the loss of a close person, exceeding cultural expectations and significantly impairing daily life and mental health [1][2] - The five stages of grief, as proposed by Elisabeth Kübler-Ross, are presented as a non-linear narrative that individuals may experience in response to significant loss [5][6] - Each stage of grief is described as an attempt to reconcile internally and move towards recovery, emphasizing that these stages are not linear and can vary in duration and order for each individual [13][14] Group 2 - The five stages of grief include Denial, Anger, Bargaining, Depression, and Acceptance, each representing different emotional responses and coping mechanisms [7][9][10][11][12] - Denial serves as a protective mechanism, allowing individuals to temporarily avoid the pain of loss [7] - Anger reflects a struggle for control and can manifest in aggressive behaviors or self-blame [9] - Bargaining involves attempts to regain control through irrational negotiations or hopes for miracles [10] - Depression is characterized by a deep sense of loss and emotional flooding, which is necessary for eventual healing [11] - Acceptance signifies a transformation of grief into a part of life, allowing individuals to carry memories tenderly [12] Group 3 - The article provides a "self-help guide" for managing negative emotions during grief, suggesting methods such as emotional expression, social connections, and engaging in activities that allow for emotional release [15][17][19][20] - It emphasizes the importance of seeking professional help when experiencing severe symptoms such as prolonged insomnia, loss of appetite, or suicidal thoughts [22][23][26] - The conclusion reiterates that grief is not a pathological state but a profound tribute to love, encouraging individuals to learn to coexist with their grief [27][28]